5 Stocks Pulling The Drugs Industry Downward

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 18 points (0.1%) at 15,482 as of Monday, July 15, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,893 issues advancing vs. 1,042 declining with 108 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.1%. A company within the industry that fell today was Novo Nordisk A/S ( NVO), up 0.7%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Drugs industry lower today. As of noon trading, Biomarin Pharmaceutical is down $1.15 (-1.8%) to $63.66 on average volume. Thus far, 753,487 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $62.87-$64.97 after having opened the day at $64.97 as compared to the previous trading day's close of $64.81.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $8.4 billion and is part of the health care sector. Shares are up 22.6% year to date as of the close of trading on Friday. Currently there are 15 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $4.43 (-3.9%) to $109.83 on heavy volume. Thus far, 3.3 million shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $107.89-$115.15 after having opened the day at $115.00 as compared to the previous trading day's close of $114.26.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $19.8 billion and is part of the health care sector. Shares are up 8.2% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.04 (-1.2%) to $86.75 on light volume. Thus far, 502,312 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $85.66-$87.63 after having opened the day at $87.09 as compared to the previous trading day's close of $87.79.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $18.8 billion and is part of the health care sector. Shares are up 102.1% year to date as of the close of trading on Friday. Currently there are 13 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Biogen Idec ( BIIB) is down $2.40 (-1.1%) to $223.94 on light volume. Thus far, 395,478 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $223.61-$228.01 after having opened the day at $228.01 as compared to the previous trading day's close of $226.34.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $53.0 billion and is part of the health care sector. Shares are up 52.6% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Bristol-Myers Squibb Company ( BMY) is down $0.45 (-1.0%) to $45.36 on light volume. Thus far, 2.5 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 10.9 million shares. The stock has ranged in price between $45.18-$45.68 after having opened the day at $45.66 as compared to the previous trading day's close of $45.81.

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $75.6 billion and is part of the health care sector. Shares are up 41.2% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 11 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Bristol-Myers Squibb Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus

Purdue Pharma Unloads Sales Staff, Transitioning From Painkiller Focus